Canalicular multispecific organic anion transporter

C. C. Paulusma, R. P. Oude Elferink et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA, J. Clin. Invest. 1998, 101, 1310-1319... 

Williams, G. C., et al. Direct Evidence that Saquinavir Is Transported by Multidrag Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2). Antimicrob. Agents Chemother. 2002, 46, 3456-3462. 

Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S., Kuwano, M., A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation, Cancer Res. 1996, 56, 4124-4129. 

Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T., Sugiyama, Y., Molecular cloning of canalicular multispecific organic anion transporter defective in EHBR, Am. J. Physiol. 1997, 272, G16-G22. 

Ni inuma, K., Nishigaki, R., Sugiyama Y., Biliary excretion of pravastatin in rats contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter, Drug Metab. Dispos. 1997, 25, 1123-1129. 

Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ et al. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997 25(6) 1539— 1542. 

Uchiumi T, Hinoshita E, Haga S, Nakamura T, Tanaka T, Toh S et al. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun 1998 252(1)703-110. 

Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y et al. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/ cMOAT) and mutations in the ATP-bind-ing-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999 64(3)739-746. 

Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K et al. Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia I I/Dubin-Johnson syndrome. Hum Mol Genet 1998 7(2) 203-207. 

Sugiyama, Y., Kato, Y., and Chu, X. (1998) Multiplicity of bdiary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol. 42(suppl), S44-S49. 

Kusuhara H, Suzuki H, Sugiyama Y. The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs. J Pharm Sci 1998 87(9) 1025-1040. 

Masuda M, I lzuka Y, Yamazaki M, et al. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Cancer Res 1997 57 (16) 3506-3510. 

Both irinotecan and SN-38 are primarily excreted into the bile by the canalicular multispecific organic anion transporter (cMOAT), a member of the ATP cassette of transporters. Therefore, inhibitors of cMOAT, such as ciclosporin, can reduce the clearance of irinotecan and SN-38 (41,42). 

---